Form 4: Cytek Director Converts RSUs to Common Stock

Cytek Biosciences Director Michael Holder converted 2,908 Restricted Stock Units into common stock on March 10, 2026, increasing his direct common stock holdings.

Summary

• Michael Holder, a Director at Cytek Biosciences, Inc. (CTKB), reported a change in beneficial ownership.
• On March 10, 2026, Holder acquired 2,908 shares of common stock through the conversion of Restricted Stock Units (RSUs).
• Following this transaction, Holder directly owns 15,267 shares of Cytek Biosciences common stock.
• The transaction also reflects a disposition of 2,908 Restricted Stock Units, reducing his RSU holdings to 10,911 units.
• Each RSU represents a contingent right to receive one share of the company's common stock.
• The RSU award has a complex vesting schedule, with portions vesting on August 18, 2024, November 18, 2024, March 10, 2025, May 18, 2025, and August 18, 2025, and annually thereafter until fully vested.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. It's a routine vesting, but the increase in direct common stock ownership by a director can be seen as a minor positive signal of alignment with shareholder interests.

Positives

• Director Michael Holder increased his direct ownership of common stock by 2,908 shares, potentially signaling confidence in the company's future.

Future Outlook

This filing, a Form 4, reports a historical insider transaction and does not contain forward-looking statements or guidance regarding the company's future outlook.

Industry Context

StockSavvy.ai notes that insider transactions, such as RSU conversions, are routine events for public company directors and executives. While this specific transaction reflects the vesting of previously granted equity, it contributes to the overall picture of insider holdings in the biotechnology and life sciences tools industry, where equity compensation is common.

Comparison to Industry Standards

• This RSU conversion is a standard mechanism for executive compensation and equity vesting, aligning with practices observed across the biotechnology and life sciences sectors.
• Companies like Bio-Rad Laboratories (BIO) and Danaher Corporation (DHR) also utilize similar equity incentive programs for their leadership, where vested RSUs convert into common stock, increasing insider ownership.

Stakeholder Impact

• Shareholders: Increased direct ownership by a director may be viewed positively as it aligns management interests with shareholder interests.

Next Steps

• Future vesting events for the remaining 10,911 Restricted Stock Units according to the detailed schedule.

Key Dates

Recommendation

This Form 4 filing reports a routine RSU conversion by a director, which is an expected part of executive compensation. It does not provide new fundamental information about the company's performance or strategic direction that would warrant a change in investment recommendation. The increase in direct stock ownership is a minor positive, but insufficient to alter a 'hold' stance based solely on this filing.

Keywords

Cytek Biosciences, CTKB, Insider Transaction, Form 4, Restricted Stock Units, RSU Conversion, Director Stock Ownership